InvestorsHub Logo
Followers 23
Posts 2760
Boards Moderated 0
Alias Born 02/23/2013

Re: None

Monday, 08/24/2015 3:34:59 AM

Monday, August 24, 2015 3:34:59 AM

Post# of 346133
Say whaaaat !

"Data generated to date have shown significant potential for combining bavituximab with agents targeting the PD-1/PDL-1 pathway and we`re excited to further explore this approach in studies with AstraZeneca`s durvalumab," said Steven W. King, president and chief executive officer of Peregrine. "AstraZeneca is a recognized leader in the immuno-oncology field and this collaboration will play a key role as we continue to fully explore the potential of bavituximab in combination immunotherapies for a variety of clinical applications."

Seriously !!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News